Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report by Piero Farruggia et al.
Farruggia et al. Journal of Medical Case Reports 2012, 6:128
JOURNAL OF MEDICAL
CASE REPORTS
http://www.jmedicalcasereports.com/content/6/1/128CASE REPORT Open AccessVocal cord palsy after vincristine treatment in a
child and the inefficacy of glutamic acid in the
prevention of relapse: a case report
Piero Farruggia1*, Serena Tropia1, Sonia Cannella1, Giuseppa Bruno1, Gaspare Oddo2 and Paolo D’Angelo1Abstract
Introduction: Vincristine is an antineoplastic drug with a well known efficacy for the treatment of acute
lymphoblastic leukemia and many solid tumors. No more than 20 pediatric patients with vincristine-induced vocal
cord palsy have been reported, and to the best of our knowledge this is the first case where glutamic acid was
administered with the aim of preventing a relapse of laryngeal dysfunction.
Case presentation: The larynx paralysis presented with hoarseness and stridor in a Caucasian 18-month-old girl
and spontaneously resolved in about a month. In order to administer a subsequent full dose of vincristine, our
patient received oral glutamic acid whose efficacy against vincristine neurological side effects has been previously
reported.
Conclusions: Since in our patient the amino acid proved to be ineffective in the prevention of laryngeal paralysis
relapse, we suggest that a dose reduction of vincristine should be preferred by oncologists as an initial approach
after a case of drug-induced vocal cord palsy.
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Vinca alkaloids have a proven role in the treatment of
hematological neoplasms. The basis of their action as
mitotic inhibitors is binding to microtubule proteins, but
they may cause axonal degeneration. In some cases, it is
likely a role in the onset of neurotoxicity can be related
to pre-existing liver dysfunction or concomitant use of
drugs such as itraconazole, phenytoin, isoniazid, erythro-
mycin, azoles or allopurinol. Rarely, vincristine (VCR)
can produce vocal cord palsy (VCP) as a consequence of
peripheral neurotoxicity involving cranial nerves, a po-
tentially life-threatening event.Case presentation
A Caucasian 18-month-old girl, born to an Italian family
and raised in Italy, with a high-risk acute lymphoblastic
leukemia (ALL) was being treated according to the AIEOP-* Correspondence: farruggia.oep@ospedalecivicopa.org; pfarruggia@libero.it
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reproduction in any medium, provided the orBFM ALL 2000 protocol. After the third dose of VCR
(1.5 mg/m2) she developed isolated hoarseness, but stridor
appeared soon after the fourth dose of VCR (last dose of in-
duction phase). A flexible fiber-optic endoscope study
showed a bilateral VCP (Figure 1). Electromyography
revealed a predominantly axonal motor neuropathy involv-
ing above the lower extremities. A nerve conduction study
of the larynx was not performed because the association of
VCR administration with significant respiratory symptoms
and immobility of the vocal folds, clearly shown by the
fiber-optic endoscope, allowed us to make a definite diag-
nosis. No side effects of VCR other than VCP were found.
Her stridor started to improve within the first seven days
and both stridor and hoarseness completely resolved
28 days after the onset of palsy: a repeat laryngoscopy study
showed normal vocal cord mobility.
Following two consolidation blocks it was decided to
administer VCR at full dose (1.5 mg/m2) first, and com-
pletely omit the second dose (scheduled just five days
later): no side effect was noted. The first reinduction
protocol II started 22 days after completion of consolida-
tion block therapy and the four weekly doses of VCRal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Vocal cord palsy: endoscopic view.
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tion (1 mg/m2).
After four weeks of interim maintenance the second rein-
duction protocol II was scheduled and the first weekly dose
of VCR was again administered at 1 mg/m2 without any
problems; then our patient received glutamic acid 1.5 g
daily orally in three divided doses and, one week later, a
bolus injection of VCR was administered at full dose. Three
days later she developed an intermittent hoarse voice last-
ing about 72 hours. Moreover, she manifested reduction of
deep tendon reflexes, neuritic calf pain (treated with oral
acetaminophen) and foot drop; the pain and foot drop
resolved after about 24 hours. The following weekly VCR
was omitted and glutamic acid was stopped after 10 days of
overall treatment. The fourth and last dose of VCR was
administered again at 1 mg/m2 and was well tolerated. She
is now in complete remission and on maintenance therapy.
Discussion
VCP appears in an early report on the use of VCR, but it
seems to be very rare; in a recent review the prevalence
among children receiving VCR was 1.36% [1]. Analyzing
the literature, we found 18 cases of children with VCR-
induced VCP (Table 1) and our patient is the fifth girl
reported [1-9].
Most cases are seen in younger children, with cases also
reported in babies [5]; the median age is 2.7 years and 12
out of 18 patients were less than three years of age. The
paralysis can be bilateral or, in about one-quarter of cases,
unilateral, with the left vocal cord seemingly much more
commonly affected (four cases versus one case of rightVCP). Swallowing problems are fairly common (about
one-third of the patients) and, apparently only when the
paralysis is bilateral, a period of mechanical ventilation
may be required. Remarkably, assisted ventilation was ne-
cessary only in five out of 18 patients [1,5,7,8]. It is fairly
certain that Down’s syndrome patients are at higher risk of
airway intervention (two out of two reported cases) [1,7].
The laryngeal dysfunction can be isolated or associated, as
in about one-third of patients, with other manifestations of
neurotoxicity, but never with other cranial neuropathies
[1-3,6,7,9]. The problem resolves in a period of one to
10 months, usually with stridor resolving before the
hoarseness. The median duration is six weeks.
The role of glutamic acid in decreasing VCR-induced
neurotoxicity has been analyzed in some studies. Re-
cently, a trial in a pediatric population [10] supported
the efficacy of glutamic acid in preventing the neuro-
logical side effects of VCR via a mechanism that remains
to be elucidated, but, to the best of our knowledge, it has
never been used after first occurrence of neurotoxicity.
In our patient glutamic acid, as rescue treatment, proved
to be ineffective and when a full dose of VCR was given
one week after a reduced dose, our patient showed not
only a reappearance of stridor and hoarseness but also a
transient peripheral neuropathy. On reviewing pediatric
cases, reintroduction of VCR at half dose was associated
with a recurrence of palsy in only one case out of six [8],
and no respiratory failure developed. In contrast, besides
our patient, there are only another two cases reported of
VCR reintroduction at full dose [1,7], and in one of them
there was a relapse [7].
Table 1 Literature review of pediatric patients with vincristine induced vocal cord palsy












Tobias and Bozeman [2] M/5 years ALL 0.5 L No No No Omitted
F/2 years NHL-T 2 L No No Yes Half dose
Annino et al. [3] M/1.5 years RMS 6 BL No Yes No Omitted
M/1.3 years Ependymoma 2 BL No No No Omitted
M/3 years ALL 2 L No No Yes Half dose
Agarwall et al. [4] F/11 years LNH NA R No No No NA
Anghelescu et al. [5] NA/0.4 years ALL 1 BL Yes Yes No NA
Graf et al. [6] M/15 years ALL + CMT 34.3 BL No No Yes NA
Ahmad et al. [7] M/3 years ALL + Down’s 38.5 BL Yes Yes No Omitted
M/1.8 years Ependymoma 34.3 BL No No No Omitted
M/2 years ALL 27 BL No Yes Yes Omitted*
Kuruvilla et al. [1] F/1 year ALL 37 BL Yes Yes No Omitted
M/4 years ALL + Down’s 20 BL Yes No Yes Half dose
M/5 years ES 7 BL No No No No indication
M/3 years RMS 4 L No Yes Half dose, then increased to
regular regimen
Latiff et al. [8] M/2 years ALL 13 BL No No No Half dose**
F/3 years ALL 40 BL Yes*** No No Half dose
Naithani et al. [9] M/14 years ALL 6 BL No Yes Yes Omitted
*Vincristine definitely omitted after symptoms recurrence in consequence of drug reintroduction at full dose (drug initially given at 25% of recommended dose and gradually increased to full dose).
**Vincristine definitely omitted after symptoms recurrence in consequence of drug reintroduction at half dose.
***Cordectomy.
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In our opinion the administration of weekly VCR at half
to two-thirds dose should be the recommended initial
approach after a case of drug-induced vocal cord palsy.
We have not found evidence that administration of glu-
tamic acid can prevent relapse of VCP.
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